Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2154777 | Nuclear Medicine and Biology | 2006 | 6 Pages |
Abstract
Vesamicol is a leading compound for positron emission tomography (PET) and single photon emission computed tomography (SPECT) tracers for mapping the vesicular acetylcholine transporter (VAChT). Recently, we found that (+)-p-methylvesamicol ((+)-PMV) has low affinity for VAChT (Ki=199 nM), but has moderate to high affinity for sigma receptors: Ki=3.0 nM for sigma1 and Ki=40.7 nM for sigma2, and that sigma1-selective SA4503 (Ki=4.4 nM for sigma1 and Ki=242 nM for sigma2) has moderate affinity for VAChT (Ki=50.2 nM). In the present study, we examined the potential of (+)-[11C]PMV as a PET radioligand for mapping sigma1 receptors as compared with [11C]SA4503. In rat brain, similar regional distribution patterns of (+)-[11C]PMV and [11C]SA4503 were shown by tissue dissection and by ex vivo autoradiography. Blocking experiments using (±)-PMV, (â)-vesamicol, SA4503, haloperidol and (±)-pentazocine showed that the two tracers specifically bound to sigma1 receptors, and that [11C]SA4503 exhibited greater specific binding than (+)-[11C]PMV. No sign of VAChT-specific binding by [11C]SA4503 was observed in the striatum, which is rich in VAChT sites. In conclusion, (+)-[11C]PMV specifically bound to sigma1 receptors in the brain, but to a lesser extent than [11C]SA4503, suggesting that (+)-[11C]PMV is a less preferable PET ligand than [11C]SA4503. On the other hand, the moderate affinity of [11C]SA4503 for VAChT is negligible in vivo.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kiichi Ishiwata, Kazunori Kawamura, Kazuyoshi Yajima, QingGeLeTu QingGeLeTu, Hirofumi Mori, Kazuhiro Shiba,